| Property |
Value |
| Gene Symbol |
BACE1 |
| Full Name |
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 |
| Chromosomal Location |
11q13.2 |
| NCBI Gene ID |
23626 |
| OMIM ID |
604252 |
| Ensembl ID |
ENSG00000186318 |
| UniProt ID |
Q15118 |
| Encoded Protein |
Beta-secretase 1, Aspartic protease |
| Associated Diseases |
Alzheimer's disease, Down syndrome, Schizophrenia |
BACE1 (Beta-Secretase 1, also known as Beta-site Amyloid Precursor Protein Cleaving Enzyme 1) is a member of the aspartyl protease family that plays a critical role in the production of amyloid-beta (Aβ) peptides in Alzheimer's disease. BACE1 is the rate-limiting enzyme responsible for the first proteolytic cleavage of the amyloid precursor protein (APP), initiating the amyloidogenic pathway that leads to Aβ generation[@vassar1999][@sinha1999].
BACE1 is a transmembrane aspartyl protease that catalyzes the ectodomain shedding of numerous type I membrane proteins. Its primary substrate is APP, which BACE1 cleaves at the beta-site to generate a soluble APPβ (sAPPβ) fragment and a membrane-bound C-terminal fragment (CTFβ). This cleavage is followed by γ-secretase cleavage of CTFβ, releasing amyloid-beta peptides of varying lengths (Aβ40, Aβ42)[@yan1999].
Beyond APP, BACE1 cleaves numerous other substrates including[@evin2015]:
- APP-like proteins (APLP1, APLP2)
- Seizure protein 6 (SEZ6)
- Close homolog of L1 (CHL1)
- Neuregulin 1 (NRG1) - critical for myelination
- Voltage-gated sodium channel subunits
- LDL receptor-related proteins
- GABA(A) receptor subunits - newly discovered mechanism of neural hyperexcitability[@zhang2025]
BACE1 is expressed at high levels in neurons, particularly in the hippocampus and cortex, brain regions most affected in Alzheimer's disease. Its activity is highest in the Golgi apparatus and endosomes, compartments where APP processing occurs[@cai2011].
¶ Discovery and History
The discovery of BACE1 represented a major breakthrough in AD research:
- 1999: BACE1 was simultaneously cloned and characterized by multiple groups
- 2000-2005: Development of first-generation BACE1 inhibitors
- 2007-2012: Multiple BACE1 inhibitors entered clinical trials
- 2013-2018: Several trials failed due to safety concerns
- 2019-Present: Renewed interest in substrate-selective and partial inhibition approaches[@jacobson2022]
BACE1 is a type I transmembrane protein with the following domains:
| Domain |
Function |
Key Features |
| Signal Peptide |
Secretory pathway targeting |
Cleaved in ER |
| Prodomain |
Enzyme maturation |
Autocatalytic cleavage |
| Catalytic Domain |
Protease activity |
Aspartyl protease motif (DTG) |
| Transmembrane Domain |
Membrane anchoring |
Single helix |
| Cytoplasmic Domain |
Signaling/transport |
Contains sorting motifs |
BACE1 uses a classic aspartyl protease mechanism:
- Pro-BACE1 undergoes autocatalytic cleavage in the secretory pathway
- The mature enzyme contains two conserved aspartate residues (DTG motif)
- These aspartates act as nucleophiles to hydrolyze peptide bonds
- Optimal cleavage site: EVKM/D(A/T)↓X motif in APP
BACE1 participates in several important physiological processes:
- APP Processing: Normal cleavage generates sAPPβ with potential neurotrophic properties
- Synaptic Function: Regulates synaptic proteins and plasticity
- Myelination: Neuregulin-1 cleavage regulates oligodendrocyte function
- Neuronal Development: Controls neuronal survival and differentiation
- Voltage-gated Channels: Modulates sodium channel function
BACE1 is central to Alzheimer's disease pathogenesis through its role in amyloid-beta production[@may2011]:
| Aspect |
Details |
| Genetic Evidence |
BACE1 expression and activity are elevated in AD brains |
| BACE1 Promoter |
Risk variants associated with increased expression |
| Therapeutic Target |
Major drug discovery focus for AD modification |
| Knockout Studies |
BACE1-/- mice show complete absence of Aβ production |
BACE1 is the rate-limiting enzyme in Aβ production, making it a prime therapeutic target. However, clinical trials have faced significant challenges:
Clinical Trial History:
| Compound |
Company |
Outcome |
| LY2811376 (Eli Lilly) |
Terminated |
Toxicity |
| LY2886721 (Eli Lilly) |
Terminated |
Liver toxicity |
| MK-8931/Verubecestat (Merck) |
Terminated |
Cognitive decline |
| E2609 (Eisai) |
Terminated |
Safety concerns |
| JNJ-54861911 (Janssen) |
Terminated |
Safety concerns |
Reasons for Trial Failures:
- Mechanism-based toxicity due to essential substrates
- Cognitive worsening with complete inhibition
- Liver toxicity
- Synaptic plasticity impairment from off-target effects on NRG1
New Approaches:
- Partial inhibition rather than complete blockade
- Substrate-specific inhibitors
- Antibody-based therapies
- Gene therapy with ASOs[@jacobson2022]
BACE1 activity is elevated in Down syndrome due to chromosome 21 trisomy:
- APP gene is on chromosome 21
- Increased APP leads to increased BACE1 processing
- Early-onset Aβ pathology in Down syndrome
BACE1 processing of NRG1 may affect neurodevelopment:
- Altered BACE1-NRG1 signaling in schizophrenia
- Potential developmental role in myelination
- May affect GABAergic signaling
BACE1 is expressed in microglia and participates in neuroinflammatory responses:
- Clusterin regulation: BACE1 regulates Clusterin expression in astrocytes, enhancing Aβ clearance[@chen2023]
- Cytokine modulation: BACE1 activity affects inflammatory cytokine production
- Phagocytosis: May influence microglial clearance functions
BACE1 in endothelial cells contributes to vascular dysfunction in AD[@mehta2024]:
- β-processing in endothelium: Contributes to cerebrovascular dysfunction
- Vascular risk factors: BACE1 links cardiovascular risk to dementia
- Blood-brain barrier: May affect BBB integrity
A recent discovery reveals autoantibodies to BACE1 may promote disease progression[@yang2024]:
- Prevalence: Present in human blood
- Mechanism: May block normal BACE1 function or alter its trafficking
- Therapeutic implications: Could affect BACE1-targeted approaches
A groundbreaking 2025 study revealed BACE1 cleaves GABA(A) receptor subunits[@zhang2025]:
- BACE1 cleaves GABA(A) receptor β subunits
- This decreases inhibitory signaling
- Contributes to neural hyperexcitability in AD
- Explains seizure susceptibility in AD
- New mechanism for BACE1 toxicity
- Suggests GABA(A)-targeted therapies
- Partial BACE1 inhibition may preserve GABA(A) function
- Combined approaches targeting both Aβ production and GABA signaling
BACE1 is widely expressed in the central nervous system:
- Highest expression: Hippocampus (CA1-CA3 pyramidal neurons), cerebral cortex (layers II-IV), amygdala
- Moderate expression: Substantia nigra pars compacta, cerebellum (Purkinje cells)
- Cellular localization: Primarily in neurons, lower expression in astrocytes and microglia
- Subcellular localization: Predominantly in Golgi apparatus, endosomes, and the plasma membrane
| Cell Type |
Expression Level |
Notes |
| Glutamatergic neurons |
High |
Primary source of BACE1 |
| GABAergic neurons |
Moderate |
Including interneurons |
| Oligodendrocyte precursors |
Moderate |
Developmental expression |
| Astrocytes |
Low |
Increases in disease |
| Microglia |
Low |
Further increases with activation |
| Generation |
Compound |
Company |
Status |
| 1st |
LY2811376 |
Eli Lilly |
Terminated (toxicity) |
| 1st |
LY2886721 |
Eli Lilly |
Terminated (liver toxicity) |
| 1st |
MK-8931 (verubecestat) |
Merck |
Terminated (cognitive decline) |
| 1st |
E2609 |
Eisai |
Terminated |
| 2nd |
JNJ-54861911 |
Janssen |
Terminated |
| 3rd |
BACE1 ASO |
Various |
In development |
- Mechanism-based toxicity: BACE1 cleaves essential substrates beyond APP
- Narrow therapeutic window: Complete inhibition causes adverse effects
- Safety margin: Preclinical models showed cognitive impairment with complete inhibition
- Multiple substrates: Off-target effects on NRG1, GABA(A) receptors, and others
- Partial inhibition: Maintaining minimal BACE1 activity
- Substrate-specific inhibitors: Targeting only APP cleavage
- Immunotherapy: Antibodies against BACE1 or Aβ
- Gene therapy: siRNA and antisense oligonucleotide approaches
- Allosteric modulators: Non-competitive inhibition
BACE1 participates in a network of interactions relevant to AD:
| Interactor |
Interaction Type |
Functional Consequence |
| APP |
Primary substrate |
Aβ production |
| γ-secretase |
Sequential cleavage |
Aβ release |
| BACE2 |
Homolog |
Potential redundancy |
| ADAM10 |
Competing protease |
Non-amyloidogenic processing |
| ApoE |
Lipid metabolism |
Aβ clearance |
| TREM2 |
Microglial signaling |
Phagocytosis |
- Vassar R, et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein (1999)
- Sinha S, et al., Purification and cloning of amyloid precursor protein beta-secretase (1999)
- Yan R, et al., Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity (1999)
- Cai J, et al., BACE1 is the major beta-secretase for generation of Abeta peptides by neurons (2011)
- May PC, et al., Robust central reduction of amyloid-beta in humans with an orally available BACE1 inhibitor (2011)
- Evin G, et al., BACE1 inhibitors: A new generation of disease-modifying drugs (2015)
- Bolognesi ML, et al., Revisiting BACE1 inhibitors for Alzheimer's disease (2019)
- Jacobson LH, et al., BACE1 inhibition as a therapeutic strategy for Alzheimer's disease (2022)
- Chen X, et al., BACE1 regulates expression of Clusterin in astrocytes (2023)
- Mehta D, et al., Cerebrovascular Endothelial Dysfunction: Role of BACE1 (2024)
- Yang L, et al., Autoantibodies to BACE1 promote Abeta accumulation (2024)
- Zhang Y, et al., BACE1-dependent cleavage of GABA(A) receptor (2025)